SciSparc Ltd. ( (SPRC) ) has issued an announcement.
On February 25, 2025, SciSparc Ltd. entered into a Securities Purchase and Exchange Agreement with MitoCareX Bio Ltd., Dr. Alon Silberman, and Prof. Ciro Leonardo Pierri to sell their shares in MitoCareX to N2OFF, Inc., making MitoCareX a wholly-owned subsidiary of N2OFF. The agreement, which includes a cash payment and shares of N2OFF common stock, is contingent on N2OFF’s stockholder approval. The transaction, approved by SciSparc’s board, could impact the company’s financial position and strategic focus by divesting its interest in MitoCareX, potentially affecting stakeholders and market positioning.
More about SciSparc Ltd.
SciSparc Ltd. is a company involved in the pharmaceutical industry, focusing on drug discovery and development. The company is engaged in computational drug discovery targeting resistant cancers, utilizing its expertise in the field of human mitochondrial carriers.
YTD Price Performance: -4.85%
Average Trading Volume: 8,980,605
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.86M
For a thorough assessment of SPRC stock, go to TipRanks’ Stock Analysis page.